Vital Signs

Printer-friendly page

January 2008

What does it take to Create Medicine of the Highest Order

Medical Center CEO Bradford C. Berk, M.D., Ph.D.

More than 80 years ago, well-known educator Abraham Flexner’s revolutionary report, Medical Education in the United States and Canada, proposed a vision of university-based medical education that would support the powerful interaction of three distinct but interrelated missions: scientific inquiry, learning, and patient care. When he looked to establish a medical school based on his philosophy in New York, Flexner told University President Rush Rhees that the University of Rochester presented an ideal place for “a medical school of the highest order.”

What does it take to create Medicine of the Highest Order? That question forms the nucleus our new strategic plan. And we found the answer in our roots: innovation, collaboration, and the ability to convert new basic science discoveries into novel therapies.

The University of Rochester Medical Center’s 2007-2012 Strategic Plan charts the course by which this Medical Center will transform from a regional medical center to a nationally respected magnet for research, teaching, patient care, and community service. It is a recipe for building strategically on our history and strengths, capturing the flow of scientific ideas to benefit patients throughout the northeastern United States.

It sets clear priorities as it calls for the boldest investment in expertise, facilities and programs since the founding of this Medical Center. This plan promises to extend the quality and breadth of our region’s health care, as it strengthens our regional economy.

We are better positioned than most other medical centers to seize this opportunity. Given our vibrant scientific portfolio, robust patient care services, financial stability, an eagerly supportive community, and the confidence of national funding agencies like the National Institutes of Health, never before has the promise of our collective planning been brighter. Because it bears the fingerprints of Abraham Flexner, I’m convinced that this plan will continue our path to Medicine of the Highest Order.

What does it take? To Chart a Course

Hear Dr. Berk’s Podcast on the Strategic Plan by going to

More than a year ago, the University of Rochester Medical Center renewed its commitment to achieve national prominence by developing a strategic plan that defines priorities, leverages opportunities, and fulfills the promise of its founders to create Medicine of the Highest Order.

The resulting URMC 2007-2012 Strategic Plan builds on the success of the Medical Center’s previous strategic plan by leveraging its powerful blend of robust science, disciplined teaching programs, and burgeoning clinical enterprise. This is a plan for using education, science and technology to create new knowledge that helps patients, advances the practice of medicine, and contributes to the economic vitality of our community.

“This plan extends the quality and breadth of our region’s health care, and strengthens our local economy. We must take these steps in order to keep our patients and our professional talent right here in Rochester,” said Medical Center CEO and Strategic Plan architecht Bradford C. Berk, M.D., Ph.D.

The centerpiece of the plan is the creation of nine high priority clinical and research programs. These are signature programs in which the Medical Center can stake its national reputation for innovation and excellence. The chosen Integrated Disease Programs and Innovative Science Programs reflect not only disease prevalence, but areas in which the Medical Center has either built considerable expertise or areas we seek to strengthen to remain competitive.

In addition, the 2007-2012 Strategic Plan determines key investments in people, technology, and facilities in the years ahead. This includes the most ambitious investment in patient care and translational science facilities in the history of the Medical Center. Because capital dollars are always limited, careful choices have been made to reflect the full range of needs and the economic imperatives that face academic medicine.

Learn More About…
Integrated Disease Programs page x
Innovative Disease Programs page x
Key Investments page 4

Visit for more Strategic Plan information.


Strategic Plan 2007-2012 Goals

We strive to provide patient care that is high-quality, safe, and infused with new knowledge that comes from our scientific research. Understanding both the challenges and the opportunities that face URMC, we have articulated the following major goals:

• To become one of the leading health care systems in the Northeast and to achieve national recognition for our high quality signature programs that develop new therapies based on outstanding research.
• To sustain an interdisciplinary environment that emphasizes fundamental discovery and fosters innovation through the acquisition of new technologies.
• To ensure translation of fundamental discovery into cutting-edge patient therapies through the education of clinicians and scientists.
• To grow clinical volume by recruiting outstanding health professionals and providing capacity for complex procedures where specialized expertise and high volume ensure the highest levels of patient safety and quality.
• To maintain clinical margin and productivity that sustains growth in the clinical and academic missions of the Medical Center.
• To engage the community though economic development (including technology transfer and research partnerships) and to promote community health through research programs that support community-based interventions.
• To ensure that all education programs at URMC are nationally outstanding and prepare students for careers of excellence.

What does it take?
To Define Our Future

To achieve the goals set forth in the 2007-2012 plan, the Medical Center has focused on nine high priority clinical and research programs. They are signature programs in which – with strategic investments in people and facilities – URMC can stake its reputation for innovation and excellence.

All told, 60 new faculty members – reprensenting a $50 million infusion of new talent – will be recruited to help us take full advantage of emerging areas of scientific inquiry that have application across all disease areas.

Integrated Disease Programs
Our research, teaching and patient care services will be organized around five major disease areas that plague large segments of our population. These Integrated Disease Programs (IDPs) reflect not only disease prevalence, but also represent disciplines in which URMC already has built considerable research and clinical expertise.

In each of these IDPs, the emphasis will be on translating basic discoveries to patient care, and developing novel therapies that extend and improve health. This will require a more integrated, more streamlined organizational structure that more closely aligns with the way patients seek care. Thus, the IDPs must create environments that span traditional departmental boundaries.

  • Cancer. Already the second leading cause of death in the U.S., cancer incidence is on the rise as our region’s population ages. Over the last five years, the James P. Wilmot Cancer Center has charted a 15 to 20 percent growth in the number of patients it treats. Since its creation in 1966, the cancer center has become recognized for its expertise in leukemia and lymphomas, urologic oncology and cancer control programs, and innovations in radiation oncology. In its new 163,000 square-foot facility, the Wilmot Cancer Center will bring outpatient clinical programs together with translational research laboratories, positioning it as the ideal cancer center to develop next generation therapies.
    Leader: Richard I. Fisher, M.D.
  • Cardiovascular disease. Since more Americans lose their lives to heart disease than any other ailment, programs to prevent and treat cardiovascular disease are crucial to the Medical Center’s strategic plan. The Medical Center has long provided comprehensive clinical expertise in all areas of cardiovascular medicine, with regionally unique programs in electrophysiology, heart failure, heart transplantation, aortic surgery, and children’s heart surgery. It also boasts nationally recognized research programs in vascular biology, atrial fibrillation, ablation, hereditary arrhythmias and use of left ventricular assist devices for heart failure patients. The Aab Cardiovascular Research Institute’s 15 basic science laboratories have won more than 60 research grants and filed 36 patent applications.
    Leader: Mark B. Taubman, M.D.
  • Immunology and infectious disease. Infectious diseases have been principal threats to health throughout the history of man. The fight against deadly microbes relies largely on knowledge of the immune system, which plays a central role in diseases like arthritis, asthma, diabetes, and atherosclerosis. Knowledge of the vast, diverse workings of the immune system – a booming field with URMC already in the vanguard – has the potential to create new approaches not yet imagined and to revolutionize the manufacture of vaccines. The University of Rochester Medical Center’s emphasis on immunology is appropriate, as the discipline is the source of the Medical Center’s greatest recognition, and its greatest royalties.
    Leader: Ignacio Sanz, M.D.
  • Musculoskeletal disease. Americans are not just living longer, but are demanding the ability to stay physically active despite aging joints and decreasing muscle and bone strength. Osteoporosis and its associated fractures, together with athletic injuries, have become the new epidemics of aging. As one of the busiest musculoskeletal services in the U.S., more than three dozen University of Rochester faculty members attend to 140,000 visits per year. This clinical expertise is complemented by the country’s top NIH-funded orthopaedic research program that seeks to prevent osteoporosis, speed fracture healing, make live bone transplants possible, and replace damaged tendons using breakthrough approaches. The integration of research and clinical care promises innovations for the Rochester community and the nation at-large.
    Leader: Regis O’Keefe, M.D., Ph.D.
  • Neuromedicine. On a national scale, diseases of the brain and spinal cord come at a cost of hundreds of billions of dollars annually, notwithstanding the suffering endured by patients and their families. Brain damage from stroke is the leading cause of long-term disability in the nation; meanwhile, the number of people diagnosed with Alzheimer’s disease is skyrocketing, expected to top 16 million by mid-century. At the Medical Center, research into these and other brain diseases currently accounts for nearly one-third of all research dollars. Regionally, Strong Memorial Hospital is already a neuromedicine powerhouse and the preferred provider of neurological and neurosurgical care. With neuromedicine touching 19 departments at the Medical Center and six more at the College of Arts, Sciences and Engineering, it’s a clear choice for emphasis and growth.
    Leader: Webster Pilcher, M.D., Ph.D.


Innovative Science Programs (ISPs)
The second major focus of the strategic plan will be to invest in emerging research areas that will catalyze discoveries within the signature programs. Four new Innovative Science Programs (ISPs) will be established, chosen because they have promising application to cancer, cardiovascular disease, immunology and infectious disease, orthopaedics, and neuromedicine. They also represent disciplines in which we already have the fundamentals of a strong program, or they represent areas we seek to strengthen in order to remain competitive.

Each new ISP will function as a virtual center, gathering together experts who already reside at the University of Rochester; in keeping with our effort to foster cross-campus collaboration, three of the new centers are joint ventures between the Medical Center and the University’s College of Arts, Sciences and Engineering. And, opportunities for commercialization exist in all four ISPs.

  • Stem Cell and Regenerative Medicine. The foremost innovative scientific program is stem cells, where cellular approaches to treat diseases and replace tissues offer great opportunity. Stem cells are early-stage cells capable of generating all the different tissues found in the body, a potential bounty of cells that can be customized to treat, in theory, almost any disease. More than 250 people in approximately 40 Rochester laboratories already work with stem cells, making the research area one of the most pervasive at the Medical Center. Exciting programs exist in neuromedicine for treating Parkinson’s Disease and spinal cord injury; in cancer, including leukemias and prostate malignancies; and within musculoskeletal specialties which are looking to regenerate bone and cartilage. Novel approaches using drugs to differentiate and manipulate stem cells are underway. Scientists at the University of Rochester are among the few to have discovered stem cells and worked out their complicated lineage. They are also among the first to display the capability of manipulating them to treat disease effectively.
    Leader: Mark Noble, Ph.D.
  • Biomedical Imaging and Biomarkers (joint with the College). The application of imaging technology makes possible entirely new approaches for early diagnosis and non-invasive treatment in diseases as diverse as heart disease, cognitive disorders, and cancer. Bioimaging allows doctors to precisely assess what is going on deep inside the body, transforming our knowledge of living tissues and even individual cells. It also makes possible the development of biomarkers for disease, biochemical changes that provide early proof that a disease is present, is getting worse, or is responding to treatment. Although collaborations between the College and the Medical Center bring together some of the world’s top imaging and optics expertise, biomedical imaging is an area where the institution must grow quickly to maintain its lead among peers.
    Leader: Maiken Nedergaard, M.D., D.M.Sc.
  • Nanomedicine (joint with the College). With a great depth of expertise both at the Medical Center and the College, nanomedicine as an innovative scientific program provides the perfect fit with Rochester’s current capabilities. The new program formally brings together more than a dozen faculty members who’ve been working in a loose confederation for nearly a decade. The economic stakes are high: In recent years, the Federal government has plowed more than $2 billion into technologies based on devices just a tiny fraction of the width of a human hair, and New York state has added another half billion. Yet while nanotechnology research has boomed, its application to human health provides a rich, largely untapped opportunity. Examples include ultra-sensitive nano-sensors to detect organisms such as bacteria, viruses, or antibodies. Nano-materials are also being used to provide the scaffolding for the growth of new tissue, providing a new way to regenerate nerves, bones, and other vital tissues.
    Co-Leaders: Benjamin L. Miller, Ph.D., Rick Waugh, Ph.D.
  • Genomics and Systems Biology (joint with the College). The Human Genome Project has created a tidal wave of information on human physiology, leaving medical scientists scrambling to invent the disciplines necessary to draw medically relevant conclusions from these data. Systems biology involves modeling with computational biology to understand gene-to-gene interactions and develop treatments that are personalized to the individual. Genomics and Systems Biology were chosen as a priority because they represent the tools needed to understand and ultimately affect the incredibly complex systems of the human body. Along with the promise these disciplines represent, they were also selected because they are already areas of strength at the University of Rochester – among scientists working in cancer, cardiovascular and immunology research. Quickly expanding the Medical Center’s capabilities to conduct high-speed genomic and systems studies will be central to research competitiveness.
    Leader: Dirk Bohmann, Ph.D.


Key Investments

The Medical Center’s 2007-2012 Strategic Plan calls for investing nearly a half billion dollars in new recruitments, new technologies, and upgraded facilities over the next several years. This investment is absolutely necessary to sustain the progress made since the 1996 plan, and take advantage of an unprecedented opportunity to set the pace nationally for translational medicine.

“Affordability has been one of our paramount concerns, since we will not mortgage our future by making commitments that are beyond our reach,” said Medical Center CEO Bradford C. Berk, M.D., Ph.D. “Therefore, we have deliberately spread our investment over several years to minimize the need to assume debt, and will take advantage of a reinvigorated Development effort that includes more public funding, foundation grants and support from individuals. Plus we’ll use royalties from the new HPV vaccine and transfers from the clinical enterprise to help finance our plans.”

The strategic plan calls for 60 new faculty recruits, representing a $50 million infusion of new talent. In addition, the plan also focuses on efforts to recruit and retain the people whose skills and insights set us apart – whether they are scientists, physicians, nurses, administrators, or others. The strategic plan calls for the following initiatives:
• Refocused and more nimble Human Resources function that will introduce new trainings and other efforts aimed at energizing employees and reducing turnover
• Expansion of employee satisfaction surveys to provide real-time feedback on employees’ ideas and concerns
Deepening our commitment to employee wellness through health risk assessments, interventions, and incentives.

URMC will spend over $5.3 million to acquire new scientific technology to support translational efforts in its signature programs. These fundamental technologies will be used to strengthen our current research cores, and also will be available to all URMC scientists. Also, over the next several years, URMC expects to invest more than $40 million enhancing its information technology infrastructure. A key focus will be the web, as it becomes the main vehicle that allows health care providers and institutions to connect with each other more seamlessly (Electronic Medical Records), answers the demand by patients for electronic access to information about their conditions and their own health care (Patient Health Record), and will facilitate clinical research (Clinical Data Warehouse), as well as cross-institutional collaboration.

Major Facilities Investments
With the recent completion of the Aab Cardiovascular Research Institute and with construction of the new Wilmot Cancer Center proceeding on-schedule, URMC leaders used this strategic planning process to develop a long-range facilities plan. The three facilities being planned for relect the full range of needs and the economic imperatives that face the Medical Center.

Pediatric Replacement and Imaging Sciences Modernization (PRISM)
The centerpiece of our clinical strategy and our efforts to boost quality and safety is the Pediatric Replacement and Imaging Sciences Modernization (PRISM) project. URMC has filed an application with the New York State Department of Health seeking approval for a two-phase process that will initially involve construction of a $259 million, six -story clinical building to house 56 private rooms for Golisano Children's Hospital, an additional 56 private rooms for adults, two floors for imaging sciences (radiology), plus an expanded pharmacy and other support space. The plan also includes the renovation of 65 beds located in the current hospital. In total, the PRISM project would add another 123 beds to Strong Memorial Hospital, expanding its licensed capacity to 862.

Given the urgency of our need, planning and design would begin immediately upon receiving State approval. Construction could begin as early as July of 2009.

Ambulatory Surgery Center
Outpatient surgery is the fastest-growing clinical activity and due to capacity constraints, URMC faculty members now perform more than 5,000 cases off-site at non-URMC facilities. Additionally, cases are routinely scheduled throughout the day and into the evening, often at times inconvenient for patients, and leaving no opportunity for renovation.

The University of Rochester Medical Center has received State approval to construct an off-site, ambulatory surgery center. The 52,000-square-foot facility will contain 10 operating rooms (ORs) and two procedure rooms, allowing the Medical Center to complete necessary renovations and expansion of its on-site ORs. URMC could begin construction as early as spring 2008, with completion slated for summer of 2009

Clinical and Translational Sciences Building (CTSB)
Construction is expected to being in ? on the CTSB, which will serve as an integrated home for clinical and translational research at the Medical Center. The new 150,000 square-foot facility will house programs and resources that help scientists and clinicians overcome the administrative, technological and regulatory challenges to advancing their research such as biostatistics and biomedical informatics departments to assist researchers in developing advanced systems of data development, storage and analysis; greater access to specialized and expensive research technologies and equipment; and programs that will increase community participation in clinical trials. The building will also house the hub of the Upstate New York Translational Research Network – a research consortium consisting of the region’s 10 major biomedical research institutions.

The CTSB also will enable the Medical Center to expand its basic science activity by freeing up 20,000 square feet of space in the MRBX research building that is currently occupied by programs slated to move into the new facility. Once renovated into wet labs, this space will accommodate 12-18 new investigators and their labs.


Faculty Spotlight

Media Clips


Anton Porsteinsson was mentioned in a Nature (Nov. 20) article about the role of pharmaceutical firms in medical education.

Research by a team led by Charles Thornton that shows promise at reversing the symptoms of muscular dystrophy was covered by the BBC (Nov. 15).

Research by Emma Robertson Blackmore about job stress and support by colleagues was mentioned in an article in the New York Times (Nov. 12).

Janet Casey spoke with Newsday (Nov. 10) after the ear infection superbug she and Michael Pichichero have been studying developed into meningitis for a Toronto child.

John Treanor talked with the Wall Street Journal (Nov. 8) about whether booster shots are always necessary.

Anderson Cooper’s CNN show (Nov. 8) spotlighted Shanna Swan’s work looking into links between chemicals in plastic and physical changes in baby boys.

The University’s research into a possible link between herpes and Alzheimer’s was featured in the BBC (Nov. 1).

Karl Kieburtz spoke with WebMD (Nov. 5) about new findings that show that painkillers such as ibuprofen may protect against Parkinson’s disease.

When the American Academy of Pediatrics announced it recommends universal screening for autism, Susan Hyman talked to Newsday (Oct. 30) about the benefits of finding affected children early.

James Aquavella’s pioneering work giving sight to blind children through corneal transplants was featured on television broadcasts across the country (Oct. 29).

Obituaries for Nobel Prize winner Arthur Kornberg ran in publications across the country (Oct. 27), (Oct. 29).

C. Michael Haben was featured (Oct. 24) in stories about a new laser procedure to remove tumors from vocal cords.

Sadhna Kohli’s work looking at potential solutions to “chemo-brain” was featured in several broadcasts (Oct. 23) nationwide.

Francisco Tausk was quoted in a story in Science (Oct. 23) and elsewhere about a broccoli ingredient potentially fighting skin cancer.

The debate over whether mercury in fish cause developmental problems in children rages on, and Gary Myers spoke to the Washington Post (Oct. 23).

Katrina Korfmacher was featured in stories at NBC affiliates (Oct. 22) across the country, talking about the limitations of store-bought, lead-testing kits.

Randy Rosier’s work identifying SMURFs as a potential culprit in osteoarthritis was featured by UPI (Oct. 22).

Michael Pichichero’s research into the rise of an ear infection superbug was widely featured on NPR’s Talk of the Nation (Oct. 19).

Work by Craig Jordan and Monica Guzman about work on a new leukemia drug was featured by ABC News (Oct. 9).


Thomas V. Caprio, M.D., a geriatrician from the University of Rochester, was named President-Elect of the State Society on Aging (SSA) of New York, an organization dedicated to the promotion of knowledge about aging and the enhancement of the quality of life for older adults throughout New York State. A senior instructor in the Division of Geriatrics and Aging, Caprio currently serves on the SSA board of directors and is Co-Chair of the SSA Social Policy Committee.

Peter J. Papadakos, M.D., director of Critical Care Medicine and professor of Anesthesiology, Surgery and Neurosurgery, participated as faculty at the 2nd International Masters Class on Acute Respiratory Failure in the Netherlands. Also released at that meeting was Papadakos’ fourth textbook: Mechanical Ventilation Clinical Applications and Pathophysiology. A number of Medical Center faculty also contributed to the book including Michael Apostolakos, M.D., associate professor of Medicine; Mark Utell, M.D., professor of Medicine and of Environmental Medicine; Irene Perillo, M.D., assistant professor of Medicine; Gary Dudek, M.D., assistant professor of Medicine; Sanjeev Chhangani, M.D., associate professor of Anesthesiology; and Denham Ward, M.D., professor of Anesthesiology and Biomedical Engineering.

Several Medical Center oncologists and surgeons were included in America’s Top Doctors for Cancer, an authoritative resource for patients seeking the best cancer care. Faculty included in the guide include Richard I. Fisher, M.D., director of the Wilmot Cancer Center and URMC vice president for clinical services, who is internationally recognized for his lymphoma care and research; Regis O’Keefe, M.D., Ph.D., chair of Orthopaedics and Rehabilitation, a specialist in cancers of the bone, muscle and soft tissue around the skeleton; Louis “Sandy” Constine, M.D., professor and vice chair of Radiation Oncology, internationally recognized for his expertise in acute and chronic effects of chemotherapy and radiation therapy on normal tissues; David Korones, M.D., associate professor of Pediatrics and Hematology/Oncology, a pediatric and adult brain tumor expert; Kristin Skinner, M.D., chief of Surgical Oncology and director of the Multidisciplinary Breast Cancer Program, recognized for surgical expertise in the removal of breast cancer, as well as her research work into biologic markers of breast cancer risk; Thomas Watson, M.D., associate professor of Surgery and chief of Thoracic Surgery, an expert in foregut (esophageal/stomach) and pulmonary surgery.

Associate Professor of Pharmacology and Physiology, Oncology and Biochemistry and Biophysics Alan V. Smrcka, Ph.D., recently was honored with the Davey Memorial Award for Outstanding Cancer Research during the 12th annual Scientific Symposium sponsored by the .James P. Wilmot Cancer Center. Smrcka, who studies the function of disease-relevant cell signaling molecules at atomic resolution, was honored for his research into the machinations of proteins and cells that could lead to development of new therapies for cancer and heart disease.

Tim Mosmann, Ph.D., director of the David H. Smith Center for Vaccine Biology and Immunology, recently won the 2008 Paul Ehrlich and Ludwig Darmstaedter Prize. The prize, which includes with a cash award of 100,000 euros, is awarded each year by a German organization to recognize achievement in Ehrlich's fields: immunology, oncology, haematology and microbiology (Ehrlich also developed the first modern chemotherapy). Mosmann received the award for his discovery of how the human immune system “decides” which cells and chemicals need to be deployed to destroy a cellular invader, a theory which continues to suggest new treatment approaches for diseases from asthma to parasitic infections.

Ashok N. Shah, M.D., professor of Medicine in the Gastroentrology and Hepatology Division, was awarded a Mastership – the American College of Gastroenterology’s highest award – for his contributions to clinical gastroenterology at the College’s Annual Meeting in October. Shah is one of only 103 physicians to earn a Mastership in the 75-year history of the College.

Catherine Lyons, R.N., M.S.; associate director for cancer services at the Wilmot Cancer Center, Margaret Carno, Ph.D., R.N., assistant professor of Nursing; and Jill Quinn, Ph.D., R.N., assistant professor of Nursing, all were recently inducted into the National Academies of Practice. Membership to this prestigious organization is only granted to those who have made substantial contributions to practice either through direct patient care, or through education and research related to the care of patients.

The American Red Cross recently introduced Red Cross ReadyRN, an on-line disaster education and training program for health professionals, authored and developed by Tener Goodwin Veenema, Ph.D., M.P.H., M.S., C.P.N.P., an associate professor at the School of Nursing and a nationally recognized expert in emergency nursing and disaster preparedness. Veenema customized the program to help the Red Cross enhance its ability to prepare for and respond to complex public health emergencies in communities across the U.S. Veenema also recently published her second textbook, Disaster Nursing and Emergency Preparedness: for Chemical, Biological and Radiological Terrorism and Other Hazards.

Robert C. Block, M.D., M.P.H., assistant professor, Division of Epidemiology, Department of Community and Preventive Medicine, recently earned a designation as a specialist in lipidology from the American Board of Clinical Lipidology. Block is one of only 300 physicians nationwide who have achieved this credential. Lipidologists specialize in the diagnosis and treatment of cholesterol disorders, which may cause atherosclerosis and heart disease.

Ruth A. Lawrence, M.D., professor of Pediatrics and medical director of the Ruth A. Lawrence Poison & Drug Information Center, is one of 22 area women who have been named finalists for this year's Women’s Councils’ Athena Award. The award recognizes a Rochester-area professional woman who has demonstrated significant achievements in business, community service and the professional advancement of women. Lawrence’s nomination focuses on her pioneer work in the field of breastfeeding medicine, on her work laying the foundations for the nation’s second-oldest poison center, and on her constant efforts to champion other women, whether they be Girl Scouts or colleagues in science and medicine.

Jinjiang Pang, Ph.D., a post-doctorate fellow within the Aab Cardiovascular Research Institute, won the American Heart Association’s Cournand and Comroe Young Investigator Prize in Cardiopulmonary and Critical Care for her work on the genetic mechanisms that control how blood vessels form in the lungs of a developing fetus. Her efforts could eventually lead to better treatment for premature infants treated with ventilators.

Thomas G. Rodenhouse, M. D., associate professor of Neurosurgery, recently was honored with the 2007 Noonan Award recipient. Given by the McQuaid Alumni Association, the Noonan Award recognizes and honors the achievements of outstanding alumni. Rodenhouse specializes in cerebrovascular malformations, aneurysms, and skull based tumors, such as acoustic neuromas.

Moira Szilagyi, M.D., Ph.D., associate professor of Pediatrics, was named the second recipient of the Calvin C. J. Sia Community Pediatrics Medical Home Leadership and Advocacy Award by The American Academy of Pediatrics’ Council on Community Pediatrics. The award recognizes a pediatrician who has demonstrated clinical excellence, community action and advocacy for children with unique care needs. Szilagyi was honored for her work as medical director at Starlight Pediatrics, a specialty clinic for foster care children and adolescents.

The Deaf Wellness Center at the University of Rochester Medical Center has received the Bronze Achievement Award from the American Psychiatric Association at a recent event in New Orleans. Robert Pollard, Ph.D., the centers director and an associate professor of psychiatry, accepted the award. The award credits the Deaf Wellness Center for its work in specialized mental health services to the deaf community and its research and education related to mental health and deafness.




Press Room Home | Search | RSS News Feeds RSS News Feed

© Copyright University of Rochester Medical Center, 2006. Disclaimer.
For questions or suggestions concerning the content of these pages, contact the URMC Webmaster.

Last updated: 02/28/2013 4:20 PM